Drugs / VPM1002BC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02371447 | Sep 2015 → Oct 2019 | urinary bladder cancer | Swiss Cancer Institute | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT04630730 | Jun 2022 → Jun 2026 overdue | urinary bladder cancer | Swiss Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VPM1002BC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04630730 ↗ |
| Known as | rBCG | “Intravesical recombinant BCG (rBCG: VPM1002BC) is applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin/gemcitabine every 3 weeks.” PMID 37286312 ↗ Jun 2023 |
| Modality | Vaccine | “VPM1002BC is a live genetically modified Mycobacterium bovis BCG that was originally developed as a vaccine against tuberculosis.” NCT02371447 ↗ |